Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy

Read more

Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide (IPN01087)

Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide (IPN01087)

3B Pharmaceuticals and Sovicell introduce a novel service offering for plasma protein binding analysis

3B Pharmaceuticals and Sovicell introduce a novel service offering for plasma protein binding analysis

KNAUER and 3B Pharmaceuticals showcase novel affinity purification process for camelid antibodies

KNAUER and 3B Pharmaceuticals showcase novel affinity purification process for camelid antibodies

Ipsen enters into a licensing agreement with 3B Pharmaceuticals to develop novel radiopharmaceuticals in oncology

Ipsen enters into a licensing agreement with 3B Pharmaceuticals to develop novel radiopharmaceuticals in oncology